ArticleActa pharmacologica Sinica2022

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.

Xiao-Ru Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.